<DOC>
	<DOCNO>NCT00635193</DOCNO>
	<brief_summary>This open-label study liposomal doxorubicin without volociximab treatment subject advance epithelial ovarian cancer primary peritoneal cancer relapse prior therapy Plat/Taxane-based chemo . Volociximab anti-angiogenic integrin inhibitor develop treatment solid tumor . Preclinical data surrogate volociximab antibody administer monotherapy indicate encourage efficacy term tumor reduction anti-angiogenic effect mouse ovarian cancer xenograft model . In clinical study , volociximab evaluate several solid tumor type , include pancreatic , renal , melanoma , many subject enter study progressive disease remain progression-free several month . In study solid tumor , volociximab show favorable safety profile administer 10 mg/kg q2wks recently 15 mg/kg qwk . A study volociximab combination liposomal doxorubicin subject ovarian cancer primary peritoneal cancer relapse prior platin/taxane therapy warrant evaluate drug 's efficacy safety . The investigator thus far activated stage 2 study 11/25 site . Worldwide , study aim enroll 150 subject .</brief_summary>
	<brief_title>Efficacy Safety Study M200 ( Volociximab Combination With Liposomal Doxorubicin )</brief_title>
	<detailed_description>This open-label study liposomal doxorubicin without volociximab treatment subject advance epithelial ovarian cancer primary peritoneal cancer relapse prior therapy Plat/Taxane-based chemo . Volociximab anti-angiogenic integrin inhibitor develop treatment solid tumor . Preclinical data surrogate volociximab antibody administer monotherapy indicate encourage efficacy term tumor reduction anti-angiogenic effect mouse ovarian cancer xenograft model . In clinical study , volociximab evaluate several solid tumor type , include pancreatic , renal , melanoma , many subject enter study progressive disease remain progression-free several month .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Females age &gt; = 18 year old time inform consent . Advanced ( Stage III IV ) histologically document epithelial ovarian cancer primary peritoneal cancer ( exclude small , roundcell histology ) . Recurrent persistent disease . Received 2 prior cancer treatment regimen , least one must include platinum/taxane base therapy . If regimen give , count one regimen . If component regimen give use schedule , count one regimen . At least 1 target lesion assess response RECIST criterion . ( Tumors within previously irradiate field designate nontarget ) Other protocoldefined inclusion criterion apply . Subjects take immunomodulatory agent include , limited , interferon , interleukin , systemic steroid , cyclosporine , tacrolimus , calcineurin inhibitor , chronic low dose methotrexate , azathioprine . ( Use inhale intranasal steroid oral steroid 10 mg/day prednisone equivalent permit . ) Subjects require treatment anti coagulant exception low dose AspirinÂ® ( 81 mg/day ) , warfarin ( 1 mg/day ) , heparin IV catheter patency Evidence bleed diathesis coagulopathy . ( Prior history DVT exclude subject participate study . ) History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 1 . Nonhealing wound , ulcer , bone fracture . Evidence autoimmune disease include , limited , ulcerative colitis , Crohn 's disease , rheumatoid arthritis , systemic lupus erythematosus , scleroderma , disease immune function immune competence know impaired . Active infection require systemic antibiotic , antiviral , antifungal include HIV/AIDS , hepatitis B , hepatitis C infection . Other protocoldefined exclusion criterion apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Ovarian neoplasm</keyword>
	<keyword>Angiogenesis inhibitor</keyword>
	<keyword>Angiogenesis</keyword>
	<keyword>Volociximab</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Antibody</keyword>
	<keyword>Monoclonals</keyword>
</DOC>